title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Materials and methods | GDM | GDM | This was a non-blinded, randomised controlled trial, that recruited 100 pregnant women diagnosed with GDM between 24 and 28 weeks of gestation at the 1st Department of Obstetrics and Gynaecology, Medical University of Warsaw. After meeting the inclusion criteria patients were randomly allocated to the study group (FGM,... | PMC10359198 |
Results | There was no significant difference in mean glycaemia between the groups ( | PMC10359198 | ||
Supplementary Information | The online version contains supplementary material available at 10.1007/s00592-023-02091-2. | PMC10359198 | ||
Keywords | PMC10359198 | |||
Introduction | hyperglycaemia, GDM | GDM, HYPERGLYCAEMIA, GESTATIONAL DIABETES MELLITUS | Gestational diabetes mellitus (GDM) is the most common type of hyperglycaemia in pregnancy, with the incidence rate of 14% varying worldwide [ | PMC10359198 |
Materials and methods | macrosomia, weight gain, GDM | EVENTS, RECRUITMENT, GDM, SECONDARY, NEONATAL HYPOGLYCAEMIA, HYPERGLYCAEMIA | We performed a non-blinded, randomised controlled trial between March 2020 and October 2022, that recruited 100 pregnant women diagnosed with GDM between 24 and 28 weeks of gestation at the 1st Department of Obstetrics and Gynaecology, Medical University of Warsaw. A diagnosis of GDM was based on 2013 World Health Orga... | PMC10359198 |
Sample size calculation | We performed a two-sided power analysis (power of 80%, significance level of 5%) and estimated a sample size of 80 patients (40 patients for each group). The sample size was further increased to 100 patients based on estimated drop-out rate of 10% participants. For the estimation, we used results of a previous study co... | PMC10359198 | ||
Statistical analysis | REGRESSION | The statistical analysis was carried out using STATA, version 17.0 (Stata Corporation, TX, USA) and GraphPad Prism v9 (GraphPad Software, CA, USA). Continuous variables were presented as means ± standard deviation (SD) or medians ± interquartile range (IQR) and categorical variables were presented as frequencies (%) by... | PMC10359198 | |
Results | PLACENTA PRAEVIA, RECRUITMENT | Between March 2020 and October 2022, we recruited 100 patients that met the inclusion criteria. 50 patients were recruited to the study group, out of which 49 completed the study (one patient was excluded after recruitment process at the first follow up visit due to diagnosis of placenta praevia). 50 patients were allo... | PMC10359198 | |
Primary outcome | GDM | GDM, GESTATIONAL DIABETES MELLITUS | There was no significant difference in mean (SD) fasting glucose concentration during the first 4 weeks following GDM diagnosis between the groups (Glycaemic control in the first 4 weeks following inclusion to the studyDelta mean glucose concentrations were significantly reduced in the study group in comparison to the ... | PMC10359198 |
Secondary outcomes | macrosomia, weight gain | EVENT, RECRUITMENT, NEONATAL HYPOGLYCAEMIA, REGRESSION, EVENTS, APPENDIX | FGM enabled to reveal all nocturnal hypoglycaemic events during the first month of the study in the study group (mean incidence of 15 events/month). In 6 out of 49 patients (12.24%) we recorded one episode of hypoglycaemic event level 2 (glucose concentration less than 54 mg/dl). We were not able to compare it with the... | PMC10359198 |
Discussion | pre-gestational diabetes, macrosomia, diabetes, GDM, weight gain, hypoglycaemia | GESTATIONAL DIABETES MELLITUS, RECRUITMENT, GDM, DIABETES, NEONATAL HYPOGLYCAEMIA, EVENTS, HYPOGLYCAEMIA | Our study revealed, that FGM might improve glycaemic control, when compared to SMBG. Although mean glycaemia did not differ significantly between the groups, and when separately analysed, postprandial glycaemia was significantly lower in the control group, glycaemia through the first month of the study improved more si... | PMC10359198 |
Conclusions | macrosomia, weight gain, GDM | GDM, NEONATAL HYPOGLYCAEMIA | In summary, FGM application resulted in significantly better improvement in glycaemic control in the 3rd and 4th week of the study. FGM led to higher EAT score, that might indicate better diet modifications after GDM diagnosis; however, it had no impact on lifestyle interventions including gestational weight gain, qual... | PMC10359198 |
Acknowledgements | RECRUITMENT | Thank you to our colleagues from the 1st Department of Obstetrics and Gynaecology, Medical University of Warsaw for helping us in the recruitment process. | PMC10359198 | |
Authors’ contributions | PJS | AM, PJS, BW and DBO conceived and planned the study. AM, PJS, JT, IR, MW and DBO recruited the participants to the study. AM, PJS, JT and DBO conducted the study and collected essential data. AM analysed data. AM, PJS and DBO drafted the manuscript. PJS and DBO revised the manuscript. All authors have contributed to re... | PMC10359198 | |
Funding | This study did not receive any funding from the public or commercial sector. | PMC10359198 | ||
Declarations | PMC10359198 | |||
Conflict of interest | The authors declare that they have no conflict of interest. | PMC10359198 | ||
References | PMC10359198 | |||
1. Introduction | obesity, metabolic syndrome, Obesity, TG | OBESITY, OBESITY, CARDIOVASCULAR DISEASES, INSULIN RESISTANCE, METABOLIC SYNDROME, TYPE 2 DIABETES, DISEASES | The aim of this study was to investigate the effects of 12 weeks of high-intensity training with astaxanthin supplementation on adipokine levels, insulin resistance and lipid profiles in males with obesity. Sixty-eight males with obesity were randomly stratified into four groups of seventeen subjects each: control grou... | PMC9866205 |
2. Materials and Methods | After calling in public places such as gyms, medical clinics, hospitals and social networks, there were 101 participants who initially volunteered for the study, of whom 33 were ineligible, leaving 68 participants in the study (mean age: 27.6 ± 8.4 yrs; mean height: 167.8 ± 3.1 cm; mean weight: 94.7± 2.0 kg; mean BMI: ... | PMC9866205 | ||
2.1. Experimental Design | One week prior to the start of the training programs, the study procedures were explained and a familiarization session was completed by all participants. Height, weight, and body composition were assessed for all the participants, who were then randomly assigned into one of four equal groups ( | PMC9866205 | ||
2.2. Body Composition and Cardio-Respiratory Fitness Assessments | Body weights and heights were measured using a calibrated scale (Seca GmbH & Co., Hamburg, Germany) and stadiometer (Seca GmbH & Co., Hamburg, Germany), respectively. Then, the body mass index (BMI, kg/m | PMC9866205 | ||
2.3. Training Protocols | In the current study, a total of 36 sessions lasting up to 60 min each were included in the HIFT program using CrossFit. Crossfit training is stratified as high-intensity functional training with a mixed model of concurrent strength and endurance performance often containing various fitness components [ | PMC9866205 | ||
2.4. Supplementation of Astaxanthin and Placebo | Eligible participants in the SG and TSG received 20 mg/day of astaxanthin capsule (Marine Product Tech. Inc., Seongnam, Republic of Korea) or matching placebo capsule (20 mg/day of raw corn starch) once daily with breakfast for 12 weeks. Participants were considered adherent when ≥80% of their prescribed supplements we... | PMC9866205 | ||
2.5. Nutrient Intake and Dietary Analysis | Before and after the experiment changes in habitual dietary intake over time were determined using three-day food records (two weekdays and one weekend day) [ | PMC9866205 | ||
2.6. Assessment of Blood Markers | MDD, TG | BLOOD, SENSITIVITY | Fasting blood samples were taken under standard conditions between 8 and 10 am from the right arm 12 h before the first exercise session and 72 h after the last session. Blood samples were transferred to EDTA-containing tubes, centrifuged for 10 min at 3000 rpm, and stored at −70 °C for later use for the following meas... | PMC9866205 |
2.7. Statistical Analysis | Descriptive statistics (means ± standard deviation) were used to summarize all data. The normality of the data was assessed by the Shapiro–Wilk test. A two-way ANOVA repeated measures test was used to determine group X time interactions. One-way ANOVA and Fisher LSD post-hoc tests were used for evaluation of baseline d... | PMC9866205 | ||
3. Results | PMC9866205 | |||
3.1. Anthropometric Characteristics and Cardio-Respiratory Parameters | There were no between-group differences in baseline values for weight (Changes in BMI after 12 weeks were significantly decreased in the SG ( | PMC9866205 | ||
3.2. Lipid Profiles | There were no significant differences in the baseline levels of HDL ( | PMC9866205 | ||
3.3. Metabolic Factors | There were no significant differences in baseline levels of glucose ( | PMC9866205 | ||
3.4. Adipokines and Growth Differentiation Factors | TG | There were no significant differences in baseline levels of CTRP9 (A comparison of pre-test and post-test values indicated no differences in CTRP9 (The analysis of between-group differences for CTRP9 indicated a significance in TG (The decreases of CTRP2 in the SG (GDF8 decreased significantly in the SG (GDF15 signific... | PMC9866205 | |
4. Discussion | obesity, obese, overweight | OBESITY, OBESE, INSULIN RESISTANCE | We examined the effects of 12 weeks of HIFT that was supplemented with astaxanthin on adipokine levels, insulin resistance and lipid profiles in males with obesity. Our findings indicate that 12 weeks of CrossFit exercise training supplemented with astaxanthin: (A) reduced anthropometric indices (body weight, BMI, FFM,... | PMC9866205 |
5. Conclusions | obesity | OBESITY | Our findings indicate that 12 weeks of astaxanthin supplementation and exercise training decreased adipokines levels, body composition (weight, %fat), anthropometrical factors (BMI), and improved lipid and metabolic profiles. These benefits were greater in men with obesity who exercised and used astaxanthin supplementa... | PMC9866205 |
Author Contributions | All authors contributed equally to data collection. They read and approved the final manuscript. Finally, all authors agreed to be accountable for all aspects of the work. All authors have read and agreed to the published version of the manuscript. | PMC9866205 | ||
Institutional Review Board Statement | All procedures were performed according to the latest revision of the Declaration of Helsinki. The Research and Ethics Committee of the Islamic Azad University approved all procedures of this study (Ethics code: IR-IAU1400-47, 8 July 2021). | PMC9866205 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC9866205 | ||
Data Availability Statement | The data presented in this study are available within the manuscript. | PMC9866205 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC9866205 | ||
References | TG | INSULIN RESISTANCE | Pre- and post-training values (mean ± SD) for CTRP9 in the control (CG), supplement (SG), training (TG), training + supplement (TSG) groups. Pre- and post-training values (mean ± SD) for CTRP2 in the control (CG), supplement (SG), training (TG), training + supplement (TSG) groups. Pre- and post-training values (mean ± ... | PMC9866205 |
Abstract | PMC10583133 | |||
Objective | To assess the clinical effectiveness of septoplasty. | PMC10583133 | ||
Design | Multicentre, randomised controlled trial. | PMC10583133 | ||
Setting | 17 otolaryngology clinics in the UK’s National Health Service. | PMC10583133 | ||
Participants | Nasal Obstruction, nasal obstruction | 378 adults (≥18 years, 67% men) newly referred with symptoms of nasal obstruction associated with septal deviation and at least moderate symptoms of nasal obstruction (score >30 on the Nasal Obstruction and Symptom Evaluation (NOSE) scale). | PMC10583133 | |
Interventions | Participants were randomised 1:1 to receive either septoplasty (n=188) or defined medical management (n=190, nasal steroid and saline spray for six months), stratified by baseline symptom severity and sex. | PMC10583133 | ||
Main outcome measures | nasal airflow | The primary outcome measure was patient reported score on the Sino-Nasal Outcome Test-22 (SNOT-22) at six months, with 9 points defined as the minimal clinically important difference. Secondary outcomes included quality of life and objective nasal airflow measures. | PMC10583133 | |
Results | bleeding, infections, nasal airflow | BLEEDING, INFECTIONS | Mean SNOT-22 scores at six months were 19.9 (95% confidence interval 17.0 to 22.7) in the septoplasty arm (n=152, intention-to-treat population) and 39.5 (36.1 to 42.9) in the medical management arm (n=155); an estimated 20.0 points lower (better) for participants randomised to receive septoplasty (95% confidence inter... | PMC10583133 |
Conclusions | nasal obstruction | Septoplasty is a more effective intervention than a defined medical management regimen with a nasal steroid and saline spray in adults with nasal obstruction associated with a deviated nasal septum. | PMC10583133 | |
Trial registration | ISRCTN Registry ISRCTN16168569. | PMC10583133 | ||
Introduction | nasal airflow, nasal obstruction | Septoplasty is a common operation to alleviate nasal obstruction associated with deviation of the nasal septum. It may be accompanied by reduction of the inferior turbinate to increase airflow through the nasal cavities. Surgery is typically predicated on clinical history and a visual assessment of the nasal septum. To... | PMC10583133 | |
Methods | The Nasal Airways Obstruction Study was a multicentre, non-adaptive, open label randomised controlled trial conducted in 17 hospitals in the UK’s NHS. The regional ethics committee approved the trial protocol. | PMC10583133 | ||
Participants | Nasal Obstruction, nasal obstruction | Participants were adults (≥18 years) newly referred to otolaryngology clinics with symptoms of nasal obstruction associated with septal deviation and confirmed by endoscopic assessment. Participants were offered entry into the trial if their presenting Nasal Obstruction and Symptom Evaluation (NOSE) | PMC10583133 | |
Randomisation | The Newcastle Clinical Trials Unit Randomisation Service, an in-house bespoke internet based system, performed randomisation centrally using permuted random blocks of variable length. All allocations were generated by an automated process within the system. Participants were randomised 1:1 to receive either surgical in... | PMC10583133 | ||
Interventions | PMC10583133 | |||
Outcome measures | PMC10583133 | |||
Primary outcome measure | CHRONIC RHINOSINUSITIS | The primary outcome measure was the score on the Sino-Nasal Outcome Test (SNOT-22) at six months (defined protocol time window −2 to 4 weeks for completion). SNOT-22 is a patient reported outcome measure that has been validated to assess symptoms related to chronic rhinosinusitis | PMC10583133 | |
Secondary outcome measures | ear/facial pain | SECONDARY | Four secondary patient reported outcome measures were assessed:• SNOT-22 score at 12 months.• SNOT-22 subscale (nose, sleep, ear/facial pain, psychological) score at baseline, six months, and 12 months.• Score on the NOSE scale at baseline, six months, and 12 months.• General quality of life, measured at baseline, six ... | PMC10583133 |
Statistical analysis | inferior turbinate reduction, airway blockage, enlargement of the inferior turbinate | REGRESSION, SECONDARY, RECRUITMENT | Analyses were performed according to a predetermined analysis plan.The planned population defining analyses included an ITT analysis, a per protocol analysis, and a per treatment analysis.
We explored the impact of the recruitment site on the primary outcome analysis by inserting the centre as a random effect with th... | PMC10583133 |
Missing data | SNOT-22 questionnaires with up to 20% of items missing were imputed with the average of the completed questions used for missing items. A sensitivity analysis using multiple imputation was also carried out that included all participants who provided consent and were randomised, including those with missing SNOT-22 scor... | PMC10583133 | ||
Sample size calculation | The sample of 378 participants was based on 90% power to detect a minimal clinically important difference of 9 points on SNOT-22, | PMC10583133 | ||
Patient and public involvement | Patient and public involvement was integrated throughout the design and conduct of the trial. More than 20 patients were consulted about the primary outcome measure, with most favouring the items covered by SNOT-22 over NOSE scale questionnaire. Patients’ views were integrated into the design to encourage any crossover... | PMC10583133 | ||
Results | Nasal Obstruction | ADVERSE EVENTS, SECONDARY, RECRUITMENT | Between 26 January 2018 and 5 December 2019, 378 eligible participants (67% men) were randomised. Baseline personal characteristics were balanced across treatment groups (Baseline characteristics of recruited participants. Values are number (percentage) unless stated otherwiseIQR=interquartile range; NOSE Nasal Obstruc... | PMC10583133 |
Treatment received | Of the 378 participants randomised, 188 were assigned to receive septoplasty and 190 were assigned to receive medical management (Flow of participants through study | PMC10583133 | ||
Primary outcome analysis | Nasal Obstruction | Patient reported symptoms improved in both groups. In those participants randomised to receive septoplasty in the ITT population (n=152), mean SNOT-22 scores were 44.5 (95% confidence interval 41.1 to 47.8) at baseline and 19.9 (17.0 to 22.7) at six months. The corresponding scores for those participants randomised to ... | PMC10583133 | |
Secondary outcomes | inferior turbinate reduction, Nasal Obstruction | SECONDARY | The improvement in SNOT-22 scores in the septoplasty group remained at 12 months but was less noticeable compared with those in the medical management group (Box plots showing summary statistics for SNOT-22 scores in intention-to-treat groups. Box represents middle 50% of data (lower quartile to upper quartile), horizo... | PMC10583133 |
Safety | ADVERSE EVENTS |
Reported serious adverse events and adverse events among all participants | PMC10583133 | |
Discussion | ear/facial pain, nasal obstruction, nasal airflow, nasal or sinus disease, inferior turbinate reduction | SECONDARY | Septoplasty results in significantly greater improvement in patient reported SNOT-22 scores at six months compared with a regimen of nasal steroid and saline sprays, and this improvement is sustained to 12 months. We therefore recommend that adults presenting with nasal obstruction associated with a deviated nasal sept... | PMC10583133 |
Limitations of this study | nasal valve dysfunction, rhinitis, Nasal obstruction, nasal obstruction | CHRONIC RHINOSINUSITIS, SECONDARY, RHINITIS, ALLERGIC RHINITIS | The study has several limitations. At baseline, more than 80% of patients had NOSE scores in the severe or extreme category. This may reflect the population currently referred to secondary care. However, the conclusions for these two subgroups were strong. The benefits for those participants with moderate baseline symp... | PMC10583133 |
Conclusions | nasal obstruction | Septoplasty is a superior treatment for nasal obstruction associated with septal deviation compared with a defined regimen of nasal steroid and saline sprays. Baseline NOSE scores can estimate the likely improvement in symptoms and guide decision making for patients and clinicians. The authors recommend that adults pre... | PMC10583133 | |
What is already known on this topic | SECONDARY | In 2014, the UK National Institute for Health and Care Research commissioned a randomised controlled trial to address the lack of high quality evidence to support nasal septoplastyA study in 2019 reported higher levels of general quality of life at 12 months in participants after septoplasty compared with those who rec... | PMC10583133 | |
What this study adds | Leigh, Paget, nasal obstruction | LEIGH, RECRUITMENT | Septoplasty is a clinically effective treatment for nasal obstruction associated with septal deviation compared with a defined regimen of nasal steroid and saline spraysParticipants who underwent septoplasty had greater improvement in nasal obstruction and quality of life, as measured using the SNOT-22 questionnaireHow... | PMC10583133 |
Ethics statements | PMC10583133 | |||
Ethical approval | The North East – Newcastle and North Tyneside 2 UK Health Research Authority Regional Ethics Committee (August 2017, study reference No 17/NE/0239). | PMC10583133 | ||
Data availability statement | The chief investigator and collaborators will act as custodians of the trial data and manage data sharing requests through ReShare, a UK online data repository recommended by the funder. Parties interested in data sharing will directly contact the chief investigator and collaborators and complete a project proforma and... | PMC10583133 | ||
Background | postoperative pain, pain | Management of acute postoperative pain is one of the major challenges in pediatric patients. Oral oxycodone has shown good pain relief in postoperative pain relief in children, but no studies have investigated intravenous oxycodone in this context. | PMC10155412 | |
Objective | postoperative pain | whether oxycodone PCIA can provide adequate and safe postoperative pain relief, in comparison to tramadol as reference opioid drug. | PMC10155412 | |
Design | a randomized, double-blind, parallel, multi-center clinical trial. | PMC10155412 | ||
Setting | five university medical centers and three teaching hospitals in China. | PMC10155412 | ||
Participants | patients aged 3-month-old to 6-year-old undergoing elective surgery under general anesthesia. | PMC10155412 | ||
Intervention | patients were randomly allocated to either tramadol (n = 109) or oxycodone (n = 89) as main postoperative opioid analgesic. Tramadol or oxycodone were administered with a loading dose at the end of surgery (1 or 0.1 mg.kg | PMC10155412 | ||
Outcomes | postoperative pain, consolability | the primary outcome was adequate postoperative pain relief, defined as a face, legs, activity, cry, and consolability (FLACC) score < 4/10 in the post-anesthesia care unit (PACU), with no need for an alternative rescue analgesia. FLACC was measured 10 min after extubation then every 10 min until discharge from PACU. An... | PMC10155412 | |
Results | postoperative pain, nausea and vomiting | tramadol and oxycodone provided a similar level of adequate postoperative pain relief in PACU and in the wards. No significant differences were either noted for the raw FLACC scores, the bolus dose demand in PACU, the time between the first bolus dose and discharge from PACU, analgesic drug consumption, bolus times req... | PMC10155412 | |
Conclusions | postoperative pain | an adequate postoperative analgesia can be achieved with intravenous oxycodone, this with less side effects than tramadol. It can therefore be a choice for postoperative pain relief in pediatric patients. | PMC10155412 | |
Trial registration | The study was registered at | PMC10155412 | ||
Key points | postoperative pain, pain | Question: Can the intravenous administration of oxycodone provide adequate postoperative analgesia in children?Findings: Oxycodone can provide well postoperative pain control in children, similar to tramadol.Meanings: For the first time, we demonstrate that administration of oxycodone intravenously can provide well acu... | PMC10155412 | |
Keywords | PMC10155412 | |||
Background | postoperative pain, nausea and vomiting | Acute postoperative pain is one of the major challenges for the anesthesiologists [Compared to adults, children should receive analgesia through the most comfortable and least painful method available. The oral administration of analgesics is straightforward and has demonstrated good effectiveness in various settings. ... | PMC10155412 | |
Materials and methods | PMC10155412 | |||
Study design | This is a randomized, double-blind, parallel, multi-center clinical trial. This study was approved by the medical ethics committee, the second affiliated hospital of Xi’an Jiaotong University (2018024), and written informed consent was approved by each patient’s legal guardian. The study was registered at | PMC10155412 | ||
Patients | Patients [3-month-old to 6-year-old, Body Mass Index (BMI) 18-29.5 kg/m | PMC10155412 | ||
Randomization and blinding | BLIND | A biostatistician who is unaware of treatments and patient follow-up, generates the random numbers using the SAS software (SAS Institute, USA) in a ratio of 1:1, named group A and group B. The randomization sequence is stored online until the end of the study (Only the biostatistician was aware of the randomization seq... | PMC10155412 | |
Procedures | postoperative pain, consolability, Pain, pain | Patients were fasting from clear liquids for 4 h and solid food for 6 h prior to undergoing anesthesia. No analgesic or antiemetic drugs were administrated before the procedure. Thirty minutes before the procedure, patients received an intramuscular administration of 0.01 mg.kgCisatracurium infusion was discontinued 30... | PMC10155412 | |
Outcomes | hypoxemia, postoperative pain | ADVERSE EVENTS, SECONDARY, BLIND | Outcome assessment was performed by researchers who were kept blind to the patient’s group assignments. The primary outcome was whether oxycodone could provide adequate postoperative pain relief after surgery in pediatric patients. The definition of adequate postoperative pain relief includes (1) the FLACC score< 4 in ... | PMC10155412 |
Statistical analysis | A pilot observational study in our center showed that the FLACC scores between the oxycodone and tramadol groups in PACU were 3.71 ± 1.71 and 4.49 ± 1.74, respectively. The sample size required was 166 patients (83 patients in each group) after calculation with two-tailed α = 0.05 and β = 0.2 using the SAS software (SA... | PMC10155412 | ||
Results | postoperative pain, pruritus, CRF, nausea & vomiting | ADVERSE EVENTS, CRF | From October 2018 to September 2019, 240 patients were screened and 21 of them were excluded (Fig.
Trial profile. Data analysis included all patients in the groups to which they were randomly assigned. CRF: case report formWe did not find any significant difference in the demographic data between oxycodone and tramado... | PMC10155412 |
Discussion | PONV, postoperative pain, nausea and vomiting, pain | ADVERSE EFFECTS, ADVERSE EFFECT | There are several reasons for the cautious use of opioids in pediatric postoperative pain management, one of which is the fear of potential severe adverse effects due to children’s young age and small size. Although oral oxycodone has been widely used for pain relief in children, there is no literature on the use of in... | PMC10155412 |
Acknowledgements | We appreciated that Prof. Krister Nilsson from Sweden kindly gave a lot of help for manuscript revision. | PMC10155412 | ||
Authors’ contributions | Zhengchen Li | Dr. Siyuan Li contributes to study design, project administration, data analysis, study conduction, data collection & analysis, and manuscript preparation; Drs. Hongfei Xiong, Yingping Jia, Zhengchen Li, Yexi Chen, Liang Zhong, Feng Liu, Shuangquan Qu, Zhen Du, Yuxia Wang, Suxia Huang, Yonghui Zhao contributed to study... | PMC10155412 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.